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In this study, four PLGAmicrosphere formulations of Olanzapine were characterized on the basis of their in vitro behavior at 37∘C,
using a dialysis based method, with the goal of obtaining an IVIVC. In vivo profiles were determined by deconvolution (Nelson-
Wagner method) and using fractional AUC. The in vitro and in vivo release profiles exhibited the same rank order of drug release.
Further, in vivo profiles obtained with both approaches were nearly superimposable, suggesting that fractional AUC could be used
as an alternative to the Nelson-Wagner method. A comparison of drug release profiles for the four formulations revealed that
the in vitro profile lagged slightly behind in vivo release, but the results were not statistically significant (𝑃 < 0.0001). Using the
four formulations that exhibited different release rates, a Level A IVIVC was established using the deconvolution and fractional
AUC approaches. A nearly 1 : 1 correlation (𝑅2 > 0.96) between in vitro release and in vivomeasurements confirmed the excellent
relationship between in vitro drug release and the amount of drug absorbed in vivo. The results of this study suggest that proper
selection of an in vitromethod will greatly aid in establishing a Level A IVIVC for long acting injectables.
1. Introduction
Establishing an IVIVC (in vitro in vivo correlation) remains a
challenge for non-oral dosage forms like long acting injecta-
bles. One reason for the lack of IVIVC is the dearth of in
vitromethods that are simple to set up and use, while suitably
mimicking in vivo conditions. The benefits of establishing an
in vitro in vivo correlation (IVIVC) have been enumerated
in numerous pharmaceutical publications spanning the last
three decades. Indeed, IVIVC has remained a topic of
constant discussion with several dosage forms, especially
solid orals, since the publication of an IVIVC guidance by
the FDA in 1997 [1]. The goal of an IVIVC is to establish
a relationship between the in vitro dissolution behavior
and in vivo performance of a drug product. An IVIVC is
generally described by a linear relationship between param-
eters derived from the in vitro and in vivo experiments as
quantified by the Pearson correlation. As defined by the FDA
guidance, these correlations have been classified under four
categories.
(i) Level A, the highest correlation, is a point to point
correlation between in vitro dissolution and in vivo
absorption over time. With a Level A correlation,
the in vitro dissolution profiles are generally super-
imposable with in vivo absorption curves or may be
made superimposable by use of an appropriate scaling
factor.
(ii) Level B is a correlation between summary parameters
such as in vitro dissolution rate and in vivo absorption
rate (e.g., mean dissolution time (MDT) versus mean
residence time (MRT)). Though frequently used, a
Level B correlation is not a point to point correlation
as it does not uniquely reflect the actual in vivo profile
due to the fact that several in vivo curves will produce
a similar MRT value or mean in vitro dissolution
curve.
(iii) Level C describes a single point comparison of the
amount dissolved in vitro at a particular time (e.g.,
𝑇
50
%) and an in vivo pharmacokinetic parameter
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(e.g., area under the curve (AUC)). Thus, a Level C
correlation is not descriptive of the complete shape
of the in vivo release profile, which is an important
aspect in the characterization of performance from
extended release drug products.
(iv) Level D is a rank order correlation that is qualitative
in nature.
Once established, an IVIVC can be used to guide for-
mulation and/or process development changes in the various
stages of drug development and also simplify any scale-up or
post-approval changes.
Additionally, an IVIVC allows setting of clinically rel-
evant in vitro dissolution specifications to ensure product
quality. A particular benefit of an IVIVC is that it can
be used to support the use of dissolution testing as a
surrogate for human bioequivalence studies, which would
reduce the number of human studies needed for drug
applications. A well-described in vitro in vivo relationship
could also be used to set clinically meaningful dissolution
specifications for monitoring drug manufacture. Though
the FDA guidance provides a framework for developing
and establishing an IVIVC, several challenges have been
noted with solid oral dosage forms, particularly, the devel-
opment of an in vitro dissolution method. Among other
variables, including the fact that the gastrointestinal envi-
ronment is highly complex, developing an in vitro dissolu-
tion method to mimic in vivo conditions is not simple or
straightforward.
Development of an IVIVC with non-oral dosage forms
is even more complex. With the increasing number of
such dosage forms being developed and commercialized
in recent years, development of an IVIVC has gained
additional significance. As such, the FDA guidance is cur-
rently applicable only to oral extended release products
and not for non-oral dosage forms like transdermals or
long acting injectables. However, a few publications have
attempted to establish an IVIVC from non-oral dosage
forms using the fundamental principles in the guidance
[2–4].
Some of the most successful non-oral dosage forms
marketed over the past decade include polymeric based
injectable dosage forms formulated using polylactide-co-
glycolide (PLGA) polymers [6, 7]. These polymers are FDA
approved for surgical sutures and implantable devices and
have excellent safety, tolerability, and toxicity [8, 9]. Further,
they are known to be biodegradable and biocompatible
as they undergo biodegradation over weeks to months
resulting in the formation of lactic and glycolic acids that
are cleared by the Krebs cycle. Several reports have doc-
umented the incorporation of a wide range of complex
therapeutics like peptides and proteins into PLGA to form
micron sized dosage forms called polymeric microspheres
[10–14]. Key advantages of delivering therapeutics using poly-
meric microspheres include sustained drug release, reduced
dosage, and fewer systemic side effects. Additional bene-
fits of using polymeric microspheres are the improvement
in patient compliance to drug therapy, primarily due to
reduced frequency of administration of the slow degrading
dosage form that releases the therapeutic in a sustained
fashion [15–19]. For this reason, long acting microsphere
dosage forms of several molecules like Risperidone (atyp-
ical antipsychotic to treat schizophrenia) and Leuprolide
(LHRH superagonist against prostate cancer) have been
developed and have achieved significant commercial success
[20–23].
Despite the advances in development of long acting
injectables, literature on the IVIVC with these dosage forms
continues to remain sparse. A major challenge cited for the
lack of IVIVC is the absence of a standardized or compendial
method to assess in vitro drug release from long acting
injectables [7]. A few authors have attempted Level A, B,
and C correlations, albeit with different methods and varying
degrees of success [2, 4, 24]. Of the methods available
to assess in vitro drug release, a dialysis based method
offers the most advantages in terms of simplicity in set-up,
ease of sampling, and reproducibility. With dialysis based
techniques, the dosage forms are entrapped inside a dialysis
bag containing media (inner media, non-sink conditions).
This dialysis bag is subsequently immersed inside a larger
vessel containing a large volume of the same media (outer
media, sink conditions), thus enabling a physical separation
of the dosage form from the outer media. As drug is
released from the dosage form and into the inner media,
it diffuses through the dialysis membrane into the outer
sink. This scenario mimics in vivo conditions where the
long acting injectable is immobilized upon subcutaneous or
intramuscular administration and surrounded by a stagnant
layer leading to slow drug diffusion due to non-maintenance
of sink conditions [25, 26]. Several adaptations of the dialysis
based techniques (e.g., dialysis bags) have been evaluated,
including the modified dialysis method that was successfully
used to study drug release from large molecules like peptides
[27].
In a previous publication by the same group, long act-
ing injectable formulations of Olanzapine (a second gen-
eration atypical antipsychotic) were prepared using four
PLGA polymers with the aim of improving effectiveness
and patient compliance for this drug. Subsequently, these
formulations were administered to rats to assess in vivo
performance and were successfully shown to provide sus-
tained in vivo levels of Olanzapine for 7 to 15 days [5]. In
the current study, the Olanzapine PLGA formulations were
further characterized for in vitro release behavior, using a
modified dialysis method, with the goal of achieving an
IVIVC.
2. Materials and Methods
2.1. Materials. Olanzapine was purchased from Cipla
Ltd., Bombay, India. PLGA having molecular weights
15, 30, 82, and 131 kDa was purchased from Boehringer
Ingelheim (Ingelheim, Germany) and Alkermes (Cambridge,
MA, USA). Spectra/Por Dialysis membranes (MWCO
300,000Da) were purchased from Spectrum Labs, Inc.,
CA. All the other chemicals were obtained commercially as
analytical grade reagents.
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2.2. Preparation of Microspheres. Olanzapine PLGA micro-
spheres were prepared by a solvent extraction/evaporation
method and recovered by filtration [5]. Briefly, a solution of
drug and polymer was injected into an aqueous continuous
phase under stirring with a Silverson L4R mixer (Silverson
machines,MA,USA) at predetermined speeds. Subsequently,
the solvents were removed by stirring after which the micro-
spheres were recovered by filtration, suspended in a suitable
vehicle, filled into vials, and freeze dried. Briefly, the four
formulations prepared were as follows:
(a) Formulation A (15 kDa, 75 : 25 lactide : glycolide),
(b) Formulation B (30 kDa, 50 : 50 lactide : glycolide),
(c) Formulation C (82 kDa, 65 : 35 lactide : glycolide),
(d) Formulation D (131 kDa, 75 : 25 lactide : glycolide).
2.3. Drug Content. Olanzapine content in the microspheres
was analyzed by a reverse phase HPLCmethod using a HPLC
C-18 column at a flow rate of 1.5mL/min. in a gradient
mode. The mobile phases were 0.1% TFA (trifluoroacetic
acid) aqueous solution and Acetonitrile with 0.1% TFA. Mea-
surements were performed in triplicate. Drug content (%)
was expressed as the “weight of drug in microspheres/weight
of microspheres × 100” and was determined to be 26, 30,
40, and 40% for Formulations A, B, C, and D, respectively
[5].
2.4. In Vitro Release. In vitro release (𝑛 = 3) was performed
using a modified dialysis method [26]. Briefly, Olanzapine
microspheres were accurately weighed and placed in a 7mL
dialysis tube (Tube-O-Dilalyzer, MWCO 300,000Da) filled
with 5mL 0.5M PBS (phosphate buffered saline), pH 7.4,
containing 0.05% Tween 80 and 0.1% sodium azide (inner
media), which in turn was placed in a 50mL tube containing
40mL of the same release medium (outer media). The
contents of the outer media were continuously stirred with
a magnetic stirrer to prevent formation of an unstirred
water layer at the outer dialyzing surface. At predeter-
mined intervals, 1.0mL samples were withdrawn from the
outer media followed by buffer replacement and HPLC
analysis.
2.5. In Vivo Study. The in vivo release of Olanzapine
from PLGA microspheres has been described previously
[5]. Briefly, male Sprague-Dawley rats (𝑛 = 6) weighing
approximately 300 g were used to evaluate in vivo per-
formance of Olanzapine microspheres. The microspheres
were injected subcutaneously at the back of the neck at a
10mg/kg dose (Formulations A and B) or 20mg/kg dose
(Formulations C and D) after reconstitution with water
for injection. Blood samples were collected from the tail
vein at specific time points. The samples were centrifuged
in Microtainer tubes (Becton Dickinson, Franklin Lakes,
NJ) and serum was collected. Serum samples were frozen
and stored at −20∘C until analysis. Serum samples were
analyzed at Medtox Laboratories location using a validated
method.
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Figure 1: In vitro release of Olanzapine PLGA microspheres.
2.6. IVIVC. The relationship between % drug released in
vitro and the percent absorbed for the four Olanzapine PLGA
formulations was assessed using two approaches.
(a) Nelson-Wagner approach: the fraction absorbed
(𝐹abs) was determined from the plasma
concentration-time data by deconvolution using
the Nelson-Wagner method as described in [28],
𝐹abs (𝑡) =
[𝐶 (𝑡) + 𝑘
𝑒
× AUC
(0−𝑡)
]
[𝑘
𝑒
× AUC
(0−inf)]
. (1)
With the Nelson-Wagner equation, the pharmacoki-
netic profile is deconvoluted to obtain the in vivo
absorption as a function of time and is plotted
alongside the in vitro release data to assess the super-
imposability of the two profiles. If the two curves are
superimposable and a linear relationship is obtained,
it suggests a strong correlation between in vivo and in
vitro drug release.
(b) Fractional AUC approach: the area under the curve
(AUC) was calculated using the trapezoidal rule
AUC (𝑡
1
− 𝑡
2
) = [
(𝐶
1
+ 𝐶
2
)
2
] × (𝑡
2
− 𝑡
1
) . (2)
The fractional AUC was determined by divid-
ing cumulative AUC at time “𝑡” with cumulative
AUC
(0−last), as described in previous publications [3,
29] and plotted along with the % drug released in
vitro. In a manner similar to the Nelson-Wagner
approach, the superimposability of the in vivo and in
vitro drug release was compared.
3. Results and Discussion
3.1. In Vitro Release. Figure 1 shows the in vitro release
fromOlanzapinemicrospheres,measured using themodified
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Figure 2: Effect of PLGA molecular weight on initial burst release
of Olanzapine.
dialysis method [26]. An initial burst of almost 10% (day
1) was observed from Formulations A and B after which
drug release from these batches was very similar through
day 30. In contrast, Formulations C and D exhibited a slight
initial burst (day 1) followed by slow release of drug through
3 days (3–7%), by which time nearly 21% of drug release
had occurred from Formulations A and B. Interestingly,
linear inverse relationship and an excellent correlation (𝑅2 >
0.99) were observed between initial burst release in vitro
and polymer molecular weight for Formulations A–C (15,
30, and 82 kDa, resp.) with a plateau noted at the high
molecular weight Formulation D (131 kDa) (Figure 2). From
day 3 to 8, Formulation C demonstrated an increase in
release rate resulting in 23% drug release while Formulation
D lagged with only 13% of drug being released. By day 15,
Formulations A and B exhibited more than 90% drug release
whereas values for Formulations C and D were around 75%
and 44%, respectively. Thus by day 15, drug release from
Formulation D was slightly less than half of that observed
with that observed with Formulations A and B. This trend
continued until complete release was achieved by all four
formulations.
Noteworthy observations from the in vitro release exper-
iments include:
(a) All four formulations exhibited initial burst release,
the extent of which was governed largely by polymer
molecular weight.
(b) Drug release profiles were sigmoidal or triphasic.
(c) Rank order of drug release was evident, with For-
mulations A and B exhibiting rapid release, and
Formulation D being the slowest.
(d) The modified dialysis method was able to suitably
capture all phases of the sigmoidal release profile and
was discriminatory in nature as it clearly demon-
strated rank order of drug release for the formulations
investigated.
Overall, the drug release profile from the four formu-
lations can be explained as follows. Once formulated as
drug-polymer microspheres, it is well known that release of
encapsulated drug from a PLGA matrix is controlled by two
phases, namely, drug diffusion through the polymer matrix
followed by polymer degradation and erosion [30]. During
the first phase, release of the encapsulated drug occursmainly
through its diffusion through the polymer matrix while
during the second phase, the release ismediated through both
diffusion of the drug and the degradation of the polymer
matrix. Drug diffusion through the polymer matrix, a slower
process, occurs during polymer hydration. Once hydrated,
the polymer undergoes bulk hydrolysis that causes rapid
polymer degradation, erosion, and loss of mass. Drug release
during the hydrolytic degradation phase (erosional phase)
occurs at a much faster pace than that during the diffusional
phase.
As such, Formulations A and B, manufactured using
low molecular weight PLGA (15 and 30 kDa, resp.), released
drug rapidly. Clearly, hydration of the polymeric matrix was
extremely rapid (within a day) due to low polymer molecular
weight leading to a fast onset of polymer erosion. Despite
the differing lactide : glycolide content in the polymers (75 : 25
in Formulation A and 50 : 50 in Formulation B), in vitro
drug release profiles were nearly superimposable for these
two formulations, indicating that lowermolecular weight was
a major determinant of drug release rate. For the higher
molecular weight PLGA (82 and 131 kDa for Formulations C
and D, resp.), a classic triphasic release profile was observed;
initial burst by day 1 was followed by diffusional release
through day 3 and subsequently, erosional release. A faster
release rate with Formulation C was not totally unexpected
due to a combination of an intermediate polymer molecular
weight in a 65 : 35 copolymer. On the other hand, a high
polymer molecular weight (131 kDa) in a slow degrading
copolymer (75 : 25 lactide : glycolide) led to slow release from
Formulation D. Obviously, the rate and extent of in vitro drug
release depended chiefly on polymer molecular weight than
the lactide : glycolide ratio of the PLGA copolymer.
3.2. In Vivo Results
3.2.1. Fraction Absorbed. Formulations A and B were admin-
istered to rats at a 10mg/kg dose while Formulations C
and D were administered at a 20mg/kg dose as shown in
Figure 3 [5]. Using the Nelson-Wagner method (described in
Section 2.6), the fraction of drug absorbed was calculated by
deconvoluting the pharmacokinetic profile to obtain the in
vivo absorption as a function of time [28]. Deconvolution
is a numerical method used to estimate the time course of
drug input using a mathematical function and is based on a
convolution integral. Once deconvoluted, the in vivo curve
is plotted alongside the in vitro release data to assess the
superimposability of the two profiles. Thus, the deconvolu-
tion approach allows comparison of in vivo release profile
with in vitro behavior.
A plot of the fraction of drug absorbed for the four
formulations is illustrated in Figure 4. As with Figure 1, the
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Figure 3: In vivo release of Olanzapine from PLGA microspheres (Formulations A and B = 10 mg/kg dose and Formulations C and D = 20
mg/kg dose) (from [5]).
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Figure 4: Fraction absorbed in vivo (Nelson-Wagner method).
four formulations can be instantly discriminated on the basis
of rank order. The profiles for Formulations A and B are
nearly identical and reveal that drug absorption from both
formulations is rapid. A slower absorption profile is noted
with Formulation C with the slowest rate of absorption for
Formulation D. Indeed, Figure 4 reveals that nearly 10% of
Olanzapine was absorbed by day 1 for the rapidly releasing
Formulations A and B, while the remaining formulations
released only about 3% at the same time point. In a manner
similar to that observed with in vitro release, an excellent
inverse linear relationship (Figure 2) was observed between
initial burst release as measured by the Nelson-Wagner
method and polymer molecular weight (𝑅2 > 0.99) for
Formulations A–C, with levels demonstrating a plateau for
the highest molecular weight microsphere formulation (For-
mulation D). By day 4, only 7% of Olanzapine was absorbed
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Figure 5: Fractional AUC profile of Olanzapine PLGA micro-
spheres.
from Formulation D whereas the value for Formulation C
was almost double that amount. Likewise, the fraction of
Olanzapine absorbed fromFormulationDwas five-fold lower
than that of Formulations A and B.This trend continued until
complete absorption was achieved for all the formulations,
albeit at different time points. A noteworthy fact is that
the in vivo drug release profiles (Nelson-Wagner method)
were triphasic for the four formulations, suggesting a similar
mechanism of release (diffusional and erosional) as observed
in vitro.
3.2.2. Fractional AUC. A plot of fractional AUC over time is
shown in Figure 5 and demonstrates a rank order behavior.
Similar to the in vitro results (Figure 1), the fractional AUC
profiles for Formulations A and B are nearly superimposable
6 International Journal of Biomaterials
and demonstrate that complete release occurs rapidly in vivo.
On the other hand, a moderate in vivo release profile is
noted for Formulation C with the slowest in vivo profile
for Formulation D. As such, the rank order for fractional
AUC profile appears similar to the in vitro release profile.
Of particular note is that fractional AUC values by day 1 are
around 11% for Formulations A and B, and between 2 and
3% for Formulations C and D are essentially indistinct from
those seen in Figure 1. Akin to the inverse linear relationship
observed between initial burst release and polymermolecular
weight (Figure 2) for in vitro release and fraction absorbed
(Nelson-Wagner method), a good correlation was observed
with fractional AUC (𝑅2 > 0.96). Further, as observed with
the in vitro release profile (Figure 1), Formulations C and
D show slow release through day 3, after which the in vivo
release rate increases rapidly until approximately 80–85%
is released after which the release rate tempers to achieve
complete release by days 30 and 45 for Formulations C and
D, respectively. Lastly, the in vivo fractional AUC plots for the
four formulations were sigmoidal in nature, similar to those
seen with in vitro drug release profiles, reaffirming that the
mechanism of release was unchanged whether in vitro or in
vivo.
3.3. IVIVC. Per the 1997 FDA guidance, three or more
formulations of different release rates are recommended
for the purpose of establishing an IVIVC [1]. Additionally,
the guidance recommends use of the Nelson-Wagner or
Loo-Reigelman method to calculate absorption profile of
the drug. Since the four formulations used in the cur-
rent study had varying release rates in vivo and in vitro,
that is, Formulations A and B had the fastest release
rate, while Formulation C was intermediate and Formu-
lation D had the slowest release rate, all four formula-
tions were selected for data analysis and to establish an
IVIVC.
Of the FDA recommended methods for IVIVC devel-
opment, the Nelson-Wagner was deemed suitable for the
current study as it is appropriate for use in drugs whose
pharmacokinetics can be fitted to one compartment model
[28]. Once the fraction absorbed is calculated, a correlation
may be obtained by comparing in vivo behavior with in vitro
release, to establish an IVIVC. Another approach suggested
by Woo et al. is to compare the fractional AUC with in
vitro release [29]. In the current study, data analysis was
performed using both approaches. Figure 4 shows the frac-
tion of drug absorbed in vivo, as determined by the Nelson-
Wagner method, while Figure 5 outlines the fractional AUC
for the four formulations. At first glance, the similarities
between Figures 1, 4, and 5 are very apparent. The release
rates for the four formulations follow a rank order where
Formulations A and B behave similarly and exhibit fast
release while Formulation C demonstrates a modest release
rate with the slowest drug release rate from Formulation
D.
A comparison between % release in vitro, % absorbed
using the Nelson-Wagner method, and fractional AUC is
depicted in Figure 6. To determine the % absorbed by the
Nelson-Wagner method, the fraction absorbed was multi-
plied by 100. A few striking observations are evident in
Figure 6.
(i) The % release in vivo curves, as fractional AUC or
using the Nelson-Wagner method, are nearly super-
imposable for the four formulations. Similar findings
were reported by Chu et al. in a study on PLGA
microspheres containing the alkaloid, Huperzine A
[3].
(ii) In vitro release lagged slightly behind in vivo release
for the four formulations. However, the in vitro curves
ramp up with a similar slope and are essentially
parallel to the in vivo profile. In a separate study, Jiang
et al. attributed the faster release rate in vivo to the
contribution of enzymes and foreign body response
[31].
Figure 7 highlights the correlation between % in vitro
release using themodified dialysis method and the % absorp-
tion, as calculated by the Nelson-Wagner method. As can
be clearly seen in the figure, an excellent linear correlation
(𝑅2 values between 0.95 to 0.98, 𝑃 < 0.0001) was obtained
for the slow, intermediate and fast releasing formulations.
The values of the slope are slightly greater than 1 (1.03–1.18)
indicating that in vivo release occurred slightly faster than in
vitro release.
An IVIVC utilizing fractional AUC (in vivo drug levels)
and in vitro drug release over time for the four formulations is
shown in Figure 8. Once again, a strong linear correlationwas
obtained (𝑅2 values between 0.95 and 0.98, 𝑃 < 0.0001) for
the four formulations. Values of the slope ranged between 1.03
and 1.18, similar to those obtained with the Nelson-Wagner
method and indicated that in vivo release proceeded slightly
faster than in vitro release. These data suggest that fractional
AUC could be used as an alternative to the deconvolution
approach to obtaining an IVIVC, similar to that reported
previously [3].
Figures 9 and 10 highlight the pooled IVIVC for the fast,
medium, and slow releasing Olanzapine PLGA formulations.
This type of an approach has been recommended by the FDA
[1] and has been used by other authors who attempted a Level
A correlation with injectable implants having varying release
rates [4]. As expected, slopes using the Nelson-Wagner
(Figure 9) and fractional AUC (Figure 10) approaches were
around 1.10 and 1.12, respectively, once again confirming that
in vivo release for the fast, medium, and slow formulations
followed a similar trend in which there was minimal lag in
vivo. The results in Figures 9 and 10 demonstrate an excellent
correlation (𝑅2 value greater than 0.96) between in vitro
release of Olanzapine from PLGA microspheres and in vivo
release, represented by fractional AUCand the FDAapproved
Nelson-Wagnermethod. To our knowledge, the results in this
study are the first time an IVIVC has been attempted and
successfully achieved with Olanzapine PLGA microspheres.
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Figure 6: Comparison of in vitro and in vivo release profiles for Olanzapine microspheres (diamonds = in vitro release, squares = fractional
AUC, and triangle = Nelson-Wagner absorption).
Further, these results suggest that assessment of in vitro
release using the modified dialysis method is an excellent
predictor of in vivo behavior of a small molecule, Olanzapine,
formulated with PLGA of varying molecular weight and
copolymer composition. Similar results were reported on
peptide PLA and PLGA microspheres. For instance, Woo et
al. used the modified dialysis method to evaluate in vitro
release from Leuprolide PLGAmicrospheres [29]. In another
study, Kostanski et al. used themodified dialysis methodwith
Orntide microspheres formulated with 50 : 50, 75 : 25, and
85 : 15 PLGA and also Orntide PLA microspheres [27].
In addition to being a regulatory requirement, studies on
IVIVC are extremely beneficial as they minimize time, labor
costs, and expenses needed to perform human or animal
studies with conventional or extended release products.
Further, having an IVIVC reduces the need for unnecessary
use of human subjects or animals to evaluate drug release
[7]. While there is plethora of IVIVC studies published on
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Figure 7: Level A IVIVC for Olanzapine PLGA microspheres using Nelson-Wagner method.
oral dosage forms, there are fewer reports on this subject
with long acting injectables, possibly due to the lack of
compendial methods that can be used to assess drug release
from extended release injectables. The research presented
in this paper has addressed this gap by using a systematic
scientific approach to selecting an in vitro release method
and establishing its suitability to predict in vivo behavior.
The work presented here also confirms that a suitable in
vitro method can be used as an indirect measurement of
drug availability for complex dosage forms such as PLGA
microspheres where formulation factors undergo extensive
evaluation prior to selection of a suitable copolymer that can
provide a desirable release pattern having clinical relevance.
4. Conclusions
A modified dialysis method was selected to characterize in
vitro behavior of Olanzapine PLGA microspheres prepared
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Figure 8: Level A IVIVC for Olanzapine PLGA microspheres using fractional AUC.
using varying molecular weights and copolymer composi-
tion. This method was able to accurately discriminate the
formulations on the basis of release rates. Rank order of
drug release in vitro and release profiles were nearly similar
to those obtained in vivo, either by deconvolution (Nelson-
Wagner method) or using the fractional AUC method. An
excellent 1 : 1 linear Level A correlation between in vitro and in
vivo release was obtained for all the formulations evaluated,
suggesting that the modified dialysis in vitro technique was
suitable for in vitro release assessment of Olanzapine PLGA
dosage forms.
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